Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;49(7):863-881.
doi: 10.1097/MPA.0000000000001597.

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

Thorvardur R Halfdanarson  1 , Jonathan R Strosberg  2 , Laura Tang  3 , Andrew M Bellizzi  4 , Emily K Bergsland  5 , Thomas M O'Dorisio  6 , Daniel M Halperin  7 , Lauren Fishbein  8 , Jennifer Eads  9 , Thomas A Hope  10 , Simron Singh  11 , Riad Salem  12 , David C Metz  13 , Boris G Naraev  14 , Diane L Reidy-Lagunes  15 , James R Howe  16 , Rodney F Pommier  17 , Yusuf Menda  18 , Jennifer A Chan  19
Affiliations

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

Thorvardur R Halfdanarson et al. Pancreas. 2020 Aug.

Abstract

This article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines panel consisted of medical oncologists, pathologists, gastroenterologists, endocrinologists, and radiologists. The panel reviewed a series of questions regarding the medical management of patients with pancreatic neuroendocrine tumors as well as questions regarding surveillance after resection. The available literature was reviewed for each of the question and panel members voted on controversial topics, and the recommendations were included in a document circulated to all panel members for a final approval.

PubMed Disclaimer

References

    1. Chan CS, Laddha SV, Lewis PW, et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun. 2018;9:4158.
    1. Jensen RT, Bodei L, Capdevila J, et al. Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms. Neuroendocrinology. 2019;108:26–36.
    1. Sonbol MB, Mazza GL, Starr JS, et al. Incidence and survival patterns of pancreatic neuroendocrine tumors over the last two decades: a SEER database analysis. J Clin Oncol. 2020;38(Suppl 4):abstr 629.
    1. Singh S, Chan DL, Moody L, et al. Recurrence in resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol. 2018;4:583–585.
    1. Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46:707–714.

MeSH terms